Llwytho...
Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
Rigosertib, via reactive oxygen species (ROS), stimulates cJun N-terminal kinases 1/2 (JNK1/2), which inactivate RAS/RAF signaling and thereby inhibit growth and survival of tumor cells. JNK1/2 are not only regulated by ROS—they in turn can also control ROS production. The prooxidant and cell death...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Biology (Basel) |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7284707/ https://ncbi.nlm.nih.gov/pubmed/32429320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biology9050099 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|